Capsicam

Quick links to important sections

Capsicam

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Capsicam

This section provides a foundational overview of the medicinal preparation Capsicam, establishing its identity, composition, and general therapeutic class, strictly excluding information related to dosage, usage instructions, side effects, or specific treatments.

Property Description
Active Ingredients Nonivamide, Camphor, Turpentine oil, Benzyl Nicotinate
Form Ointment (Semi-solid dosage form)
Pharmacological Class Local Irritant, Rubefacient, Topical Analgesic
Route of Administration Cutaneous (Applied to the skin)
Origin Combination of synthetic (Nonivamide) and naturally derived components
General Purpose Providing localized comfort for musculoskeletal pain

What Type of Medicine is Capsicam?

Capsicam is a combination drug classified as a topical preparation, specifically an ointment, belonging to the pharmacological classes of Local Irritants, Rubefacients, and Topical Analgesics. It is typically sold as an over-the-counter (OTC) medicine. It is designed exclusively for cutaneous application, delivering its therapeutic effect directly to the affected area. This semi-solid dosage form is characteristic of treatments intended to remain highly localized. Topical analgesic preparations and rubefacients are commonly utilized for providing localized relief for muscle and joint discomfort. The drug’s class is recognized as an approach for easing discomfort in musculoskeletal tissues.


Active Ingredients and Composition

Capsicam's efficacy is derived from a complex formula containing four primary active ingredients: Nonivamide, Camphor, Turpentine oil, and Benzyl Nicotinate. This specific multi-component composition is a differentiating factor from single-ingredient topical preparations. Nonivamide is a synthetic capsaicinoid, a chemical analogue of natural capsaicin, which is the compound responsible for the thermal sensation. The inclusion of Benzyl Nicotinate functions as a vasodilator agent in topical applications, promoting hyperemia (increased local blood flow). This blend of a potent irritant and a local vasodilator distinguishes the ointment, which relies on the synergistic action of both synthetic and naturally derived components to achieve its targeted effect within its hydrophobic base.


What is the General Purpose of This Ointment?

The general purpose of Capsicam is to provide localized comfort and temporary relief for discomfort associated with musculoskeletal pain and localized pain syndromes. The preparation is engineered to deliver a strong, localized warming effect that utilizes the principle of counterirritation, a physiological process where intense superficial sensory input distracts from deeper pain signals. Capsaicinoids and their synthetic derivatives are applied for managing localized pain symptoms. The primary active component is utilized to help manage chronic localized pain. By utilizing this mechanism, the ointment generally helps manage symptoms like muscle aches (myalgia) and joint discomfort (arthralgia).

Regulatory References

  1. Turpentine Oil Drug Information
  2. Rubefacient (Cochrane Review Abstract)
  3. Vasodilator (MedlinePlus Medical Encyclopedia)
  4. Hyperemia definition (NCI Dictionary)
  5. Cochrane Review on Capsaicin
  6. Myalgia (Muscle Pain)
  7. Arthralgia (Joint Pain)

What side effects are possible with Capsicam?

Possible Side Effects and Safety Information

The regulatory safety profile for this topical preparation is primarily structured around expected application site reactions, which are classified as the most frequent adverse events. These reactions are typically related to the preparation's function as a local irritant and rubefacient, containing the capsaicinoid Nonivamide.


Frequency-Classified Adverse Reactions

The most Common or expected effects noted in official regulatory documents are local reactions such as a burning sensation, erythema (redness), pain, and pruritus (itching) at the application site. These effects are generally considered transient, with the intensity officially documented to often diminish after the initial several days of regular use. Less common reactions may include application site dermatitis, urticaria, or inflammation.

Regulatory documents also list high-level effects grouped by System-Organ Class, including Nervous System Disorders (e.g., headache), Gastrointestinal Disorders (e.g., nausea), and transient effects on Vascular or Cardiac Disorders (e.g., hypertension, palpitations) in certain datasets.


Serious Safety Considerations

Although rare, Serious Adverse Reactions documented in regulatory sources include severe blistering or second-degree burns at the application site. Severe irritation of the Respiratory Tract, potentially leading to shortness of breath, is a risk if the product is accidentally inhaled or contacts mucous membranes.

Population and Condition-Specific Constraints are explicitly noted in the labeling. The product is not suitable for use in children. Furthermore, the preparation must not be applied to broken, damaged, or irritated skin.


Safety-Related Restrictions

Official labeling contains specific constraints related to context of use. The local burning sensation may be intensified by exposure to heat, such as hot water, sun exposure, or exercise, immediately before or after application. Strict warnings mandate the avoidance of contact with eyes and all mucous membranes.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile defines overdose risk primarily through the potential for systemic toxicity following accidental ingestion of the ointment. Due to a toxic component, this exposure is classified as potentially severe and life-threatening.

Overdose Scope Component Official Regulatory Statement
Documented overdose presentations Gastrointestinal effects (oral burning, nausea, vomiting); Central Nervous System (CNS) excitation (confusion, tremors, agitation), rapidly progressing to seizures and subsequent CNS depression [1.1, 1.4].
Physiological systems affected CNS, Gastrointestinal system, Respiratory system (potential for apnoea and respiratory failure), and potential hepatic/renal injury [1.1, 1.4].
Population-specific overdose notes Children are documented as a high-risk population for severe toxicity and potential fatality following accidental ingestion [1.1, 1.7].
Overdose Classification & Action Official Regulatory Statement
Severity classification Classified as potentially severe or life-threatening, particularly due to the risk of seizures [1.4].
Emergency-response statement Seek immediate medical help or contact Poison Control immediately upon known or suspected ingestion [1.1, 1.2]. DO NOT make the person throw up unless instructed by a healthcare professional [1.1].
Antidote/Management Constraint No specific antidote is known; treatment is limited to symptomatic and supportive measures, including controlling convulsions and monitoring vital signs [1.1, 1.7].

Connection to the overall overdose profile

Regulatory documents define the overdose profile by the swift onset of systemic neurological toxicity that necessitates emergency intervention for symptoms such as seizures and respiratory compromise [1.4]. The official guidance explicitly mandates that immediate medical attention is required for any suspected ingestion, emphasizing that care is restricted to supportive treatment due to the lack of a specific antidote [1.1, 1.7].

Therapeutic Uses of Capsicam

What Capsicam Treats: Main Uses and Benefits

The primary role of Capsicam is to provide targeted symptomatic support for discomfort arising from soft tissues. It is applied across domains where additional symptomatic support is needed, especially when localized pain, stiffness, and aching interfere with normal function and comfort. The capsaicinoid class is relevant for easing symptoms related to physical discomfort.


Symptom Relief and Therapeutic Context

Capsicam is commonly used to help with symptom clusters related to physical discomfort, such as muscle stiffness and aches, or localized joint discomfort. This is relevant for managing symptoms that may arise from common minor soft tissue issues, including localized discomfort associated with sprains and muscle strains. It is relevant in contexts involving heightened systemic burden, such as episodes after physical exertion or recurrent symptomatic manifestations. The localized relief may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

“The preparation is relevant for managing symptoms that interfere with daily comfort, and supports general well-being during symptomatic phases.”


QuickFact

Quick Fact: Relief for Musculoskeletal Pain

Capsicam is commonly used across conditions presenting with localized acute or episodic discomfort. It helps address symptom clusters that may become intense or disruptive, such as muscle stiffness and strain-related aches, thereby assisting with maintaining functional stability.

Regulatory References

  1. NIH National Library of Medicine

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility profile for Capsicam is strictly defined by regulatory documents, specifying the approved age groups and mandatory exclusions (contraindications) for use.

Eligibility Status Defined Population or Condition
Contraindicated Hypersensitivity to the active ingredients (Nonivamide, Camphor, Turpentine oil, Benzyl Nicotinate) or excipients.
Contraindicated Application on broken, irritated, or damaged skin (including ulcers and skin diseases).
Authorized Use Adults and the Older Adult/Elderly population.
Not Recommended Children and Adolescents due to a lack of sufficient safety and efficacy data.
Not Recommended Use during Pregnancy or Breastfeeding; safety is not established.

Official Eligibility Statements

Official labeling mandates that the medicine must not be used by individuals with known ingredient hypersensitivity or on any site with compromised skin integrity. The preparation is authorized for use in adults but is formally not recommended for pediatric populations, pregnant individuals, or breastfeeding mothers due to insufficient safety data documented by regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The regulatory profile for Capsicam, a topical ointment, primarily documents interactions based on localized administration restrictions rather than systemic drug-drug interactions. This focus is consistent with the minimal systemic absorption expected from the cutaneous route, which is generally insufficient to cause clinically significant effects on systemic metabolism or plasma concentrations of co-administered medicines.

Documented Interaction Constraints

Interaction Type Interacting Substance/Condition Regulatory Constraint
Pharmacodynamic (Local) Other Topical Analgesic Agents Co-administration on the same application site is restricted to avoid additive local irritant effects, such as increased burning or redness.
Pharmacodynamic (Physical) External Heat Sources (e.g., heating pads, hot water, saunas) Application is restricted immediately before or after exposure to external heat or heat-inducing activities, as this can significantly intensify the localized sensation.

Structure of the Official Profile

The official interaction structure is defined by two key constraints. The first is a site-specific restriction where the co-application of other topical preparations is restricted to prevent pharmacodynamic reinforcement. The second involves mandatory timing separation from conditions that increase skin temperature. No formal drug-drug interactions that alter systemic exposure (e.g., via CYP enzymes) are documented in the regulatory labeling for this topical preparation.

Mechanism of Action

The drug's primary mechanism involves the synthetic capsaicinoid, Nonivamide, which acts as an agonist on the Transient Receptor Potential Vanilloid 1 ( TRPV1) receptor found on peripheral sensory nerves. This interaction causes intense initial nerve activation followed by rapid desensitization or defunctionalization, leading to an interruption of the peripheral nociceptive signaling pathway. This molecular sequence results in a sustained decrease in the transmission of subsequent afferent nociceptive input.

The immediate physiological response is shaped by Camphor and Nonivamide, which generate competing sensory signals, a process known as counter-irritation. Camphor activates the TRPM8 channel (cooling sensation) while inhibiting the TRPA1 channel (pain/itch signal), creating a complex sensory input. This complex sensory input generates a competing signal that physiologically modulates the local afferent input.

The components Benzyl Nicotinate and Turpentine oil rapidly induce vasodilation by relaxing the local vascular smooth muscle. This increase in local microcirculation (hyperemia) reinforces the warming effect and potentially facilitates the penetration of the capsaicinoids. This localized vascular enhancement improves tissue perfusion and contributes to the overall local physiological response.

Dosage and Administration Information

How to Use Capsicam

This section outlines the administration guidelines for Capsicam Ointment, focusing on the procedural instructions for topical rubefacients and capsaicinoids.


Administration Protocol

The ointment is intended exclusively for cutaneous application, meaning it is applied directly to the surface of the skin. The standard adult regimen is established for individuals 18 years of age and older. Use in younger populations requires consultation with a healthcare professional. The proper application amount is a thin film of the preparation, which should be sufficient to cover the affected area, and must be gently rubbed in until fully absorbed.


Dosing Schedule and Duration

Capsicam should be applied 3 to 4 times daily, and applications must not exceed four total administrations within a 24-hour period. Consistent daily use is necessary to achieve the intended effect. If the condition does not show improvement after 7 consecutive days of use, the application course should be stopped.


Application Requirements

Administration involves specific constraints tied to proper use. The treated area must not be tightly bandaged or wrapped following application. Furthermore, the application site should not be exposed to external heat, such as from a heating pad or hot water, immediately before or after the ointment is applied. Users must thoroughly wash their hands with soap and water immediately following each application, unless the hands themselves are the area being treated.

Recent Clinical Evidence

Capsicam: Recent Clinical Evidence

The research base for this multi-component preparation was evaluated in studies of the topical counterirritant drug class and trials focusing on the key active component, Nonivamide. The findings described here outline the structure of the existing evidence, focusing on what research has explored and what data show patterns related to, without giving individual predictions.


Evidence for Localized Musculoskeletal Pain

The evidence for use in the context of muscle aches and joint discomfort is often generalized from systematic reviews of the capsaicinoid drug class. These studies examined outcomes related to physical discomfort, utilizing patient-reported outcomes describing perceived discomfort and functional status in adult populations. Findings describe patterns observed in the studies over short durations, but evidence is limited regarding the full context of how this specific formulation may be used for all types of chronic pain.


Short-Term Trials and Research Gaps

Research for acute issues like muscle strains was evaluated in short-term Randomized Controlled Trials (RCTs) focusing on outcomes describing episodic or acute changes. The studies examined primary metrics such as change in pain upon movement over brief intervals, typically one week. A significant limitation is that comparative evidence is lacking for the specific pattern of response observed with the complete four-component ointment versus its individual parts.


Duration and Different Patient Groups

The majority of observation periods are short-term, meaning observed long-term patterns are not fully established for sustained use. Furthermore, the populations was studied for this preparation and its class have been primarily adults. Data for certain groups remain insufficient, particularly for pediatric populations (children and adolescents), as studies generally exclude participants below the age of 18. Evidence highlights what is known — and what is still uncertain regarding its utility across diverse health profiles.

Frequently Asked Questions (FAQ)

Common questions about Capsicam (FAQ)


Q: How quickly can I expect to notice any effect from Capsicam?

A: According to official product information, the initial sensation of warmth or irritation is typically rapid. However, the maximal temporary relief associated with this preparation may build up over a period of about two to four weeks of regular application. This process is necessary to achieve the full benefit described in studies.


Q: How long does the effect of one application of Capsicam last?

A: Official guidelines specify that this preparation is intended for regular application, typically 3 to 4 times daily. The dosing schedule is structured to support continuous therapeutic activity throughout the day, as efficacy may decrease if used less frequently.


Q: What is the difference between Capsicam and other common topical treatments?

A: Official documentation describes Capsicam as a combination drug, which is a key differentiating factor. It contains four primary active ingredients, including the synthetic capsaicinoid Nonivamide, Camphor, and Benzyl Nicotinate. This multi-component formula places it specifically within the Local Irritant and Rubefacient pharmacological class, relying on counter-irritation and increased local blood flow for its effect.


Q: Does Capsicam interact with common over-the-counter pain relievers?

A: The regulatory profile for this topical preparation does not document formal systemic drug-drug interactions with other medicines, including oral pain relievers. This is consistent with the minimal systemic absorption expected when the product is applied only to the surface of the skin.


Q: Is it okay to use Capsicam if I'm taking blood thinners?

A: Regulatory documents indicate that there are no formal systemic drug-drug interactions documented with blood thinners because only minimal absorption into the bloodstream is expected. Official labeling for this drug class notes warnings regarding potential transient cardiovascular effects in certain patient datasets, which are a required point of consideration for individuals with cardiovascular conditions.


Q: What happens if I apply Capsicam more often than recommended?

A: Official warnings state that exceeding the recommended application schedule, such as applying more than four times in 24 hours, may lead to an increased risk of severe application site reactions. This includes signs like excessive redness, severe irritation, or blistering of the skin. If signs of skin injury occur, regulatory bodies advise seeking medical attention.


Q: Does exercise or heat (like a hot bath) increase the effects of Capsicam?

A: Yes, official labeling explicitly states that the local burning sensation caused by the ointment can be intensified by exposure to heat. This includes heat from strenuous exercise, as well as external sources like a hot bath, hot water, or saunas, when applied immediately before or after.


Q: Does the research suggest Capsicam works better for certain types of discomfort than others?

A: Research has focused on the product class for its use in localized musculoskeletal pain, which includes discomfort often associated with muscle aches, joint problems, and arthritis. The evidence base has also explored the capsaicinoid component’s utility in certain types of nerve-related pain conditions.


Q: Is the burning sensation a sign that the medicine is working?

A: The initial warming or burning sensation is an expected and common effect resulting from the activation of sensory nerves by the active ingredient. Official documents note that while the sensation is part of the drug’s physiological action, this intensity is expected to diminish after the initial several days of regular use.


Q: Can I apply makeup or lotion over the area where Capsicam was used?

A: Regulatory guidance restricts the use of other topical preparations on the same area where the medicine is being applied. This caution applies to other topical medicines, cosmetics, and non-medicinal skin care products like lotions, as co-application may affect the ointment's action or increase skin irritation.


Q: What is the typical duration of treatment with Capsicam?

A: For conditions such as muscle aches and joint discomfort, official regulatory documents commonly advise using the preparation for a period of 3 to 4 consecutive weeks. Following this period, the course of treatment is intended to be evaluated.


Q: Is there any research on using Capsicam for nerve-related discomfort?

A: Official research summaries confirm that the evidence base for this preparation's drug class has been examined for use in localized neuropathic pain (discomfort related to nerves). The understanding of its utility in this area is often drawn from systematic reviews of the capsaicinoid drug class.


Q: Does Capsicam have a distinct smell?

A: While specific odor details are not universally listed in regulatory documents as an adverse event, the product contains Camphor and Turpentine oil as active ingredients. These compounds are widely known to possess strong, distinct odors due to their chemical properties.


Q: Is the medication absorbed into the bloodstream?

A: Official pharmacokinetic information describes the systemic absorption following topical application as minimal and transient. This means that any amount absorbed into the bloodstream is expected to be very low or not detectable, and generally considered insufficient to cause effects throughout the body.


Q: What happens if a pet licks the area where Capsicam was applied?

A: Official warnings state that all medicines, including Capsicam, must be stored out of the reach and sight of children and pets. If the product is accidentally ingested or swallowed by a pet, regulatory bodies require contacting a Poison Control Center or seeking veterinary medical help.


Q: Is Capsicam approved for use on the face or scalp?

A: Regulatory guidance advises against application to the face or scalp. This restriction is in place to prevent the risk of unintentional exposure to sensitive areas like the eyes or other mucous membranes, as the ointment can cause severe local irritation.


Q: How does the concentration of the active ingredient affect its sensation on the skin?

A: Official documentation notes that the intensity of the initial burning sensation is directly related to the action of the active component and varies among different individuals. It is officially expected that this intense effect will diminish over the first several days of consistent application as the skin adapts.


Q: Is Capsicam considered generally safe for short-term use?

A: Yes, official labeling indicates the product is specifically intended for the temporary relief of minor aches and pains of muscles and joints. This designation is consistent with its authorized use profile for short-term management of acute musculoskeletal discomfort.


Q: How do regulatory bodies classify Capsicam (e.g., prescription vs. over-the-counter)?

A: The medicine is generally classified by regulatory bodies as an over-the-counter (OTC) topical preparation. This means it is authorized for self-medication by consumers for the temporary relief of minor aches and pains, without requiring a prescription.


Q: Does repeated use change how the skin reacts to Capsicam?

A: Yes, official documents describe that a change in skin reaction is expected with continuous use. The initial application site reaction, especially the burning sensation, is typically documented to diminish after the initial several days of regular and continuous application.


Q: What is the legal indication for Capsicam in the US or Europe?

A: The legal indication, as defined in regulatory documents, is for the temporary relief of minor aches and pains of muscles and joints. This covers symptoms associated with simple backache, muscle strains, sprains, and discomfort related to arthritis.

How should Capsicam be stored and disposed of?

Capsicam Ointment must be stored and disposed of strictly according to regulatory label requirements to maintain product stability and safety.

Official Storage Requirements

The ointment must be stored at Controlled Room Temperature (CRT), specifically between 20°C and 25°C (68°F and 77°F). It is required to protect the medicine from moisture and freezing. Do not store the product in a freezer.

For stability, the preparation must be stored in its original container and the container must be kept tightly closed when not in use. As with all medicines, Capsicam must be stored out of the reach and sight of children.

Disposal

Any unused or expired Capsicam Ointment must be disposed of according to local regulatory requirements. Consumers should consult local drug take-back programs for the safest method of discarding the product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Capsicam found in:

A-Z Index: